CoChat
Sign Up
Cited by 17Nonmelanoma Skin Cancer StudiesProtease and Inhibitor MechanismsSkin Protection and Aging

Differential expression of degradome components in cutaneous squamous cell carcinomas

Open access
Prasad, Nijaguna B, Fischer, Anne C, Chuang, Alice Y, Wright, Jerry M, Yang, Ting, Tsai, Hua-Ling, Westra, William H, Liegeois, Nanette J +2 more·2014·Modern Pathology
DOI 10.1038/modpathol.2013.217PMC PMC4251465
Open this paper in CoChat — free account

Abstract

Although the cure rate for cutaneous squamous cell carcinoma is high, the diverse spectrum of squamous cell carcinoma has made it difficult for early diagnosis, particularly the aggressive tumors that are highly associated with mortality. Therefore, molecular markers are needed as an adjunct to current staging methods for diagnosing high-risk lesions, and stratifying those patients with aggressive tumors. To identify such biomarkers, we have examined a comprehensive set of 200 histologically defined squamous cell carcinoma and normal skin samples by using a combination of microarray, QRT-PCR and immunohistochemistry analyses. A characteristic and distinguishable profile including matrix metalloproteinase (MMP) as well as other degradome components was differentially expressed in squamous cell carcinoma compared with normal skin samples. The expression levels of some of these genes including matrix metallopeptidase 1 (MMP1), matrix metallopeptidase 10 (MMP10), parathyroid hormone-like hormone (PTHLH), cyclin-dependent kinase inhibitor 2A (CDKN2A), A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), FBJ osteosarcoma oncogene (FOS), interleukin 6 (IL6) and reversion-inducing-cysteine-rich protein with kazal motifs (RECK) were significantly differentially expressed (P≤0.02) in squamous cell carcinoma compared with normal skin. Furthermore, based on receiver operating characteristic analyses, the mRNA and protein levels of MMP1 are significantly higher in aggressive tumors compared with non-aggressive tumors. Given that MMPs represent the most prominent family of proteinases associated with tumorigenesis, we believe that they may have an important role in modulating the tumor microenvironment of squamous cell carcinoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/modpathol.2013.217

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Squamous cell carcinoma is the second most common type of non-melanoma skin cancer and is responsible for roughly 20% of all skin cancer cases discovered.

    “Squamous cell carcinoma is the second most common type of non-melanoma skin cancer.It is responsible for roughly 20% of all skin cancer cases discovered”

    From Skin protection from solar ultraviolet radiation using natural compounds: a review (2024) · cites this paper as Prasad et al. 2014

    The paper’s Abstract says basal cell carcinoma and squamous cell carcinoma are the two most common non-melanoma skin cancers, with basal cell carcinoma far more frequent. The Discussion reports that squamous cell carcinoma accounts for approximately 20% of cutaneous malignancies in lighter-skinned populations, particularly Caucasians; it does not establish that percentage for all skin cancer cases without that population qualifier. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 55

  1. [1]Rogers HW Weinstock MA Harris AR Incidence estimate of nonmelanoma skin cancer in the United States, 2006 Arch Dermatol 2010 146 283 287 20231499
  2. [2]Diepgen TL Mahler V The epidemiology of skin cancer Br J Dermatol 2002 146 Suppl 61 1 6 11966724
  3. [3]Housman TS Feldman SR Williford PM Skin cancer is among the most costly of all cancers to treat for the Medicare population J Am Acad Dermatol 2003 48 425 429 12637924
  4. [4]Housman TS Williford PM Feldman SR Non-melanoma skin cancer: an episode of care management approach Dermatol Surg 2003 29 700 711 12828693
  5. [5]Alam M Ratner D Cutaneous squamous-cell carcinoma N Engl J Med 2001 344 975 983 11274625
  6. [8]Cherpelis BS Marcusen C Lang PG Prognostic factors for metastasis in squamous cell carcinoma of the skin Dermatol Surg 2002 28 268 273 11896781
  7. [9]Friedman GD Tekawa IS Association of basal cell skin cancers with other cancers (United States) Cancer Causes Control 2000 11 891 897 11142523
  8. [10]Efird JT Friedman GD Habel L Risk of subsequent cancer following invasive or in situ squamous cell skin cancer Ann Epidemiol 2002 12 469 475 12377424
  9. [11]Ulrich C Kanitakis J Stockfleth E Skin cancer in organ transplant recipients—where do we stand today? Am J Transplant 2008 8 2192 2198 18782290
  10. [12]Arora A Attwood J Common skin cancers and their precursors Surg Clin N Am 2009 89 703 712 19465206
  11. [13]Leiter U Garbe C Epidemiology of melanoma and nonmelanoma skin cancer—the role of sunlight Adv Exp Med Biol 2008 624 89 103 18348450
  12. [14]Edge SE Byrd DR Compton CC Cutaneous squamous cell carcinoma and other cutaneous carcinomas. chapter 29 AJCC Cancer Staging Manual 2010 7th edn 301 314
  13. [15]Puente XS Sanchez LM Overall CM Human and mouse proteases: a comparative genomic approach Nat Rev Genet 2003 4 544 558 12838346
  14. [16]Skrzydlewska E Sulkowska M Koda M Proteolytic-antiproteolytic balance and its regulation in carcinogenesis World J Gastroenterol 2005 11 1251 1266 15761961 PMC4250670
  15. [17]Egeblad M Werb Z New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2002 2 161 174 11990853
  16. [18]Farasat S Yu SS Neel VA A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics J Am Acad Dermatol 2011 64 1051 1059 21255868 PMC4659347
  17. [19]Bolstad BM Irizarry RA Astrand M A comparison of normalization methods for high density oligonucleotide array data based on variance and bias Bioinformatics 2003 19 185 193 12538238
  18. [20]Tusher VG Tibshirani R Chu G Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci USA 2001 98 5116 5121 11309499 PMC33173
  19. [21]Ekins S Nikolsky Y Bugrim A Pathway mapping tools for analysis of high content data Methods Mol Biol 2007 356 319 350 16988414
  20. [22]Eisen MB Spellman PT Brown PO Cluster analysis and display of genome-wide expression patterns Proc Natl Acad Sci USA 1998 95 14863 14868 9843981 PMC24541
  21. [23]Prasad NB Kowalski J Tsai HL Three-gene molecular diagnostic model for thyroid cancer Thyroid 2012 22 275 284 22280184 PMC3286810
  22. [24]Kerkela E Saarialho-Kere U Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer Exp Dermatol 2003 12 109 125 12702139
  23. [25]Hudson LG Gale JM Padilla RS Microarray analysis of cutaneous squamous cell carcinomas reveals enhanced expression of epidermal differentiation complex genes Mol Carcinog 2010 49 619 629 20564339 PMC3626076
  24. [26]Ra SH Li X Binder S Molecular discrimination of cutaneous squamous cell carcinoma from actinic keratosis and normal skin Mod Pathol 2011 24 963 973 21743436
  25. [27]Dooley TP Reddy SP Wilborn TW Biomarkers of human cutaneous squamous cell carcinoma from tissues and cell lines identified by DNA microarrays and qRT-PCR Biochem Biophys Res Commun 2003 306 1026 1036 12821146
  26. [28]Nindl I Dang C Forschner T Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling Mol Cancer 2006 5 30 16893473 PMC1569867
  27. [29]Haider AS Peters SB Kaporis H Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia J Invest Dermatol 2006 126 869 881 16470182
  28. [30]Dallas PB Gottardo NG Firth MJ Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR—how well do they correlate? BMC Genom 2005 6 59 PMC1142514 15854232
  29. [31]Hong DS Angelo LS Kurzrock R Interleukin-6 and its receptor in cancer: implications for translational therapeutics Cancer 2007 110 1911 1928 17849470
  30. [32]Lederle W Depner S Schnur S IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines Int J Cancer 2011 128 2803 2814 20726000
  31. [33]Oh J Takahashi R Kondo S The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis Cell 2001 107 789 800 11747814
  32. [34]Noda M Takahashi C Recklessness as a hallmark of aggressive cancer Cancer Sci 2007 98 1659 1665 17725805 PMC11158385
  33. [35]Clark JC Akiyama T Thomas DM RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model Cancer 2011 117 3517 3528 21287525
  34. [36]Namwat N Puetkasichonpasutha J Loilome W Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases J Gastroenterol 2011 46 664 675 21076843
  35. [37]Rabien A Ergun B Erbersdobler A RECK overexpression decreases invasive potential in prostate cancer cells Prostate 2012 72 948 954 22025325
  36. [38]Shen B Zheng MQ Xu XY Expression of MT1-MMP and RECK protein in human gastric carcinoma Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2011 25 364 367 22338226
  37. [39]Song SY Son HJ Nam E Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer Eur J Cancer 2006 42 101 108 16324834
  38. [40]Masui T Doi R Koshiba T RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis Clin Cancer Res 2003 9 1779 1784 12738734
  39. [41]Span PN Sweep CG Manders P Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma Cancer 2003 97 2710 2715 12767082
  40. [42]Furumoto K Arii S Mori A RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing cysteine-rich protein with Kazal motifs Hepatology 2001 33 189 195 11124835
  41. [43]van der Jagt MF Sweep FC Waas ET Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer Cancer Lett 2006 237 289 297 16046057
  42. [44]Takenaka K Ishikawa S Kawano Y Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer Eur J Cancer 2004 40 1617 1623 15196549
  43. [45]Zhang Y Cheng S Zhang G Low expression of RECK indicates a shorter survival for patients with invasive breast cancer Cancer Sci 2012 103 1084 1089 22404079 PMC7685079
  44. [46]Meng N Li Y Zhang H A novel matrix metalloproteinase regulator Histol Histopathol 2008 23 1003 1010 18498076
  45. [47]Noda M Oh J Takahashi R RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling Cancer Metas Rev 2003 22 167 175 12784995
  46. [48]Rabien A Burkhardt M Jung M Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy Eur Urol 2007 51 1259 1266 16806661
  47. [49]Rhee JS Coussens LM RECKing MMP function: implications for cancer development Trends Cell Biol 2002 12 209 211 12062160
  48. [50]Rocks N Paulissen G El Hour M Emerging roles of ADAM and ADAMTS metalloproteinases in cancer Biochimie 2008 90 369 379 17920749
  49. [51]Duffy MJ McKiernan E O’Donovan N Role of ADAMs in cancer formation and progression Clin Cancer Res 2009 15 1140 1144 19228719
  50. [52]Baren JP Stewart GD Stokes A mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma Br J Cancer 2012 107 143 149 22677901 PMC3389427
  51. [53]Stokes A Joutsa J Ala-Aho R Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma Clin Cancer Res 2010 16 2022 2035 20305301
  52. [54]Nelson AR Fingleton B Rothenberg ML Matrix metalloproteinases: biologic activity and clinical implications J Clin Oncol 2000 18 1135 1149 10694567
  53. [55]Hida Y Hamada J Differential expressions of matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs and their endogenous inhibitors among histologic subtypes of lung cancers Anticancer Agents Med Chem 2012 12 744 752 22292754
  54. [56]Riddick AC Shukla CJ Pennington CJ Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues Br J Cancer 2005 92 2171 2180 15928670 PMC2361819
  55. [57]Zhang X Zhu S Luo G Expression of MMP-10 in lung cancer Anticancer Res 2007 27 2791 2795 17695449

Cited by

Sorted by citations

Authors
Prasad, N. B., Fischer, A. C., Chuang, A. Y., Wright, J. M., Yang, T., Tsai, H.-L., Westra, W. H., Liegeois, N. J., Hess, A. D., & Tufaro, A. P.
Affiliations
  • Johns Hopkins University (US)
  • The University of Texas Southwestern Medical Center (US)
Corresponding author
  • Prasad, Nijaguna B
  • Tufaro, Anthony P
ORCID
Venue
Modern Pathology
Publisher
Elsevier BV
Published
2014-07
Volume
27
Issue
7
Pages
945-957
ISSN
0893-3952 (ISSN-L)
DOI
10.1038/modpathol.2013.217
PMC
PMC4251465
OpenAlex
W2063334934
Cited by
17
References
0
Citations by year
2024: 1 · 2023: 2 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 4 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 1
FWCI
0.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Modern Pathology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA006973)
Topics
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Health Sciences › Medicine › Dermatology › Skin Protection and Aging
Keywords
cutaneous squamous cell carcinoma, degradome, matrix metalloproteinases, MMP-1, MMP-10, tumor aggressiveness, biomarkers, tumor microenvironment, CDKN2A, ADAMTS1, FOS, interleukin-6, RECK, PTHLH, gene expression profiling
MeSH terms
Carcinoma, Squamous Cell, Humans, Skin, Skin Neoplasms, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Tissue Array Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review